MARKET

CTIC

CTIC

CTi Biopharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.250
-0.080
-6.02%
After Hours: 1.230 -0.02 -1.60% 19:46 08/07 EDT
OPEN
1.210
PREV CLOSE
1.330
HIGH
1.280
LOW
1.180
VOLUME
1.13M
TURNOVER
--
52 WEEK HIGH
1.950
52 WEEK LOW
0.6200
MARKET CAP
92.10M
P/E (TTM)
-1.7885
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CTIC stock price target is 3.500 with a high estimate of 4.000 and a low estimate of 3.000.

EPS

CTIC News

More
CTI BioPharma Reports Second Quarter 2020 Financial Results
CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the second quarter and six months ended June 30, 2020.
PR Newswire · 1d ago
The Daily Biotech Pulse: Aurinia's Kidney Inflammation Drug Filing Accepted For Review, Intuitive Surgical's Q2 Beat
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21)
Benzinga · 07/22 11:24
OPK, NBEV among premarket gainers
Seeking Alpha - Article · 07/21 12:23
NVAX, MFGP, RUN and TOPS among midday movers
Seeking Alpha - Article · 07/07 16:43
NVAX, LVGO among premarket gainers
Seeking Alpha - Article · 07/07 12:18
3 Coronavirus Penny Stocks With Triple-Digit Upside Potential
TipRanks · 07/07 00:47
Here is What Hedge Funds Think About CTI Biopharma Corp. (CTIC)
Insider Monkey · 06/22 20:27
US STOCKS-Wall Street closes higher as recovery signs soothe protest, pandemic worries
Reuters · 06/01 21:22

Industry

Biotechnology & Medical Research
-0.18%
Pharmaceuticals & Medical Research
+0.08%

Hot Stocks

Symbol
Price
%Change

About CTIC

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (IST), such as the ongoing maintenance therapy trial in patients with ovarian cancer.
More

Webull offers kinds of CTI BioPharma Corp stock information, including NASDAQ:CTIC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTIC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CTIC stock methods without spending real money on the virtual paper trading platform.